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Abstract
Osteoarthritis (OA) is characterized by alterations to
subchondral bone as well as articular cartilage. Changes to
bone in OA have also been identified at sites distal to the
affected joint, which include increased bone volume fraction and
reduced bone mineralization. Altered bone remodelling has
been proposed to underlie these bone changes in OA. To
investigate the molecular basis for these changes, we
performed microarray gene expression profiling of bone
obtained at autopsy from individuals with no evidence of joint
disease (control) and from individuals undergoing joint
replacement surgery for either degenerative hip OA, or fractured
neck of femur (osteoporosis [OP]). The OP sample set was
included because an inverse association, with respect to bone
density, has been observed between OA and the low bone
density disease OP. Compugen human 19K-oligo microarray
slides were used to compare the gene expression profiles of
OA, control and OP bone samples. Four sets of samples were
analyzed, comprising 10 OA-control female, 10 OA-control
male, 10 OA-OP female and 9 OP-control female sample pairs.
Print tip Lowess normalization and Bayesian statistical analyses
were carried out using linear models for microarray analysis,
which identified 150 differentially expressed genes in OA bone
with t scores above 4. Twenty-five of these genes were then
confirmed to be differentially expressed (P < 0.01) by real-time
PCR analysis. A substantial number of the top-ranking
differentially expressed genes identified in OA bone are known
to play roles in osteoblasts, osteocytes and osteoclasts. Many of
these genes are targets of either the WNT (wingless MMTV
integration) signalling pathway (TWIST1, IBSP, S100A4,
MMP25, RUNX2 and CD14) or the transforming growth factor
(TGF)-β/bone morphogenic protein (BMP) signalling pathway
(ADAMTS4, ADM, MEPE, GADD45B, COL4A1 and FST).
Other differentially expressed genes included WNT (WNT5B,
NHERF1, CTNNB1 and PTEN) and TGF-β/BMP (TGFB1,
SMAD3, BMP5 and INHBA) signalling pathway component or
modulating genes. In addition a subset of genes involved in
osteoclast function (GSN, PTK9, VCAM1, ITGB2, ANXA2,
GRN, PDE4A and FOXP1) was identified as being differentially
expressed in OA bone between females and males. Altered
expression of these sets of genes suggests altered bone
remodelling and may in part explain the sex disparity observed in
OA.
Introduction
Osteoarthritis (OA) is a complex, multifactorial, age-depend-
ent degenerative disease of the synovial joints. It affects the
knee and the hip most commonly, and females at a higher rate
than males, particularly after the menopause [1]. OA is charac-
terized by changes to all components of the joint, with degen-
eration and loss of articular cartilage and changes to the
subchondral bone being constant factors in disease progres-
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space narrowing, there is thickening and sclerosis of subchon-
dral bone, development of cysts and bony overgrowth at the
margins of the joint. Despite an increase in bone volume
fraction, the subchondral bone is mechanically weaker in OA
because of hypomineralization, increased collagen metabo-
lism and altered bone remodelling [3,4]. Evidence from animal
models of OA suggests that the changes in the density and
metabolism of subchondral bone develop concomitantly with
the signs of cartilage damage [5-7]. In addition, there is now
evidence in animal OA models that antiresorptive agents,
which inhibit subchondral bone remodelling, also prevent the
bone changes and loss of cartilage seen in OA, thus reducing
joint damage [8,9]. A human trial of an antiresorptive agent
also showed clear trends toward improvement in both joint
structure and symptoms in patients with primary knee OA [10].
These findings are consistent with the hypothesis that OA is a
bone disease, rather than – or in addition to – a cartilage dis-
ease, and that the structural and compositional changes seen
in OA subchondral bone, brought about by altered bone
remodelling, contribute to the breakdown of the articular carti-
lage at the joint [11-14].
There is also evidence that the osteoblasts in subchondral
bone can influence chondrocyte and cartilage metabolism
more directly, leading to abnormal remodelling of OA cartilage
[15,16]. In articular joints there is a complex juxtaposition of
vascular elements, subchondral bone and the different carti-
lage layers, with important communication between these tis-
sues [17]. These observations point to a clear interplay
between bone and cartilage at articular joints and show that
these tissues represent a functional cellular and molecular unit
[18]. Altered angiogenesis could also be contributing to the
changes seen in OA bone and cartilage, because important
inter-relationships between bone remodelling, chondrogenic
and angiogenic processes are now emerging [19-21].
In addition to the changes observed in subchondral bone,
there is growing evidence for generalized involvement of bone
in the pathogenesis of OA. Studies investigating bone at sites
distal to the joint cartilage degeneration, such as the intertro-
chanteric (IT) and medial principal compressive regions of the
proximal femur, and the iliac crest, have yielded evidence of
altered bone composition and increased bone volume in OA
compared with control individuals [22-25]. It has been pro-
posed that these structural and compositional changes reflect
systemic differences in OA bone remodelling compared with
control bone, and when these changes operate in subchon-
dral bone they can contribute to the breakdown of the articular
cartilage and eventual failure of the joint [11-14]. Furthermore,
an inverse association between OA and the low bone density
disease osteoporosis (OP) has been observed. OA patients
rarely proceed to osteoporotic fracture, suggesting that OA
has a protective effect on progression of OP. Conversely, OA
is reported to be rare in OP individuals [26].
The structural and compositional changes seen in OA bone
are likely to have considerable genetic input because there is
a significant heritable component to OA, as judged by genetic
studies [27]. Interestingly, many of the candidate susceptibility
genes for OA identified by genetic screening approaches have
bone-related functions, further suggesting the involvement of
bone in OA. Primary OA candidate genes identified, with
bone-related functions, include COL1A1, VDR, ESR1, IGF1,
SFRP3, BMP5 and TGFB1 [27-30]. SFRP3 encodes a decoy
receptor for WNT (wingless MMTV integration) ligands and
plays a role in osteoblast differentiation [31]. The WNT signal-
ling pathway is a major developmental pathway that is involved
in cell fate, differentiation and proliferation. This signalling
pathway has also been linked to skeletal development and
bone pathologies such as OP [32]. The identification of
TGFB1 and BMP5, a member of the transforming growth fac-
tor (TGF)-β superfamily, as OA susceptibility loci has impli-
cated the TGF-β/BMP signalling pathway in OA pathogenesis.
The TGF-β/BMP signalling pathway plays important roles in
development, cell proliferation and differentiation, and it has
also been shown to influence bone mass and bone remodel-
ling [33,34].
Complementing the human genetic studies described above,
and in support of altered bone remodelling at sites distal to the
active subchondral disease site, we previously identified differ-
ences in the expression of known skeletally active genes in
human trabecular bone obtained from the IT region from indi-
viduals with hip OA, as compared with bone from the same
site in control individuals. Genes identified as differentially
expressed include downregulated osteoclastogenic factor
genes (RANKL, RANK, IL6 and IL11) and upregulated bone
formation marker genes (ALPL, BGLAP, SPP1 and COL1A2)
[35-37]. Others have identified in OA individuals altered levels
of insulin-like growth factor-1, insulin-like growth factor-2 and
TGF-β1 in cortical bone from the iliac crest [38]; matrix metal-
loproteinase (MMP)2 and liver alkaline phosphatase in
subchondral bone [4]; and IL-1β, IL-6 and TGF-β1 in human
primary subchondral osteoblasts [39].
In the present study, we used microarray analysis to survey
comprehensively the expression levels of many thousands of
genes simultaneously in trabecular bone from the IT region of
the proximal femur and to compare gene expression in bone
from OA, control and OP individuals. We identified altered
expression of WNT and TGF-β/BMP signalling pathway and
target genes in OA bone. The genes include those with known
or suspected roles in osteoblast, osteocyte and osteoclast dif-
ferentiation and function, supporting a role for altered bone
remodelling in OA pathogenesis.
Materials and methods
Human bone samples
For the OA and OP groups, tube saw bone biopsies (10 mm
diameter and 20 to 40 mm long) were obtained from the ITPage 2 of 21
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patients (14 females [age range 49 to 83 years] and 10 males
[50 to 85 years]) undergoing hip arthroplasty for primary OA
and from 10 patients (10 females [74 to 87 years]) undergoing
hip arthroplasty for a fractured neck of femur (designated OP).
For the control group, trabecular bone from the IT region was
obtained during 21 autopsies (11 females [43 to 85 years]
and 10 males [50 to 85 years]) of individuals who were known
not to have suffered from any chronic condition or disease that
may have affected the skeleton. In selecting the OA, OP and
control individuals, those with a known history of medication
that might have affected bone metabolism were excluded.
Informed consent was obtained for the collection of these
specimens, with approval from the Royal Adelaide Hospital
Research Ethics Committee (protocol number 030309).
The surgical and autopsy femoral heads were graded for OA
according to the criteria of Collins [40]. Primary OA femoral
heads were either grade III or IV, and the graded autopsy fem-
oral heads were not worse than grade II and predominantly
were grade I. Surgical IT trabecular bone specimens from OA
and OP individuals were collected within 12 to 24 hours
(stored at 4°C in sterile RNase-free phosphate-buffered
saline). Control bone was collected within 24 to 72 hours after
death.
Trabecular bone in the IT region of the proximal femur, includ-
ing the marrow, was sampled, permitting analysis of the total
contribution of the bone microenvironment. The IT region was
also chosen because the trabecular structure in this region
depends on stresses in the proximal femoral shaft, while being
unaffected by the secondary sclerotic and cystic changes that
are often seen in the OA femoral head as the destruction of the
cartilage proceeds. By comparing the OA and OP samples
with control samples, the contribution to changes in gene
expression associated with surgery as opposed to autopsy
could be assessed.
RNA extraction
For total RNA extraction, the trabecular bone samples were
rinsed briefly in diethylpyrocarbonate-treated water and then
separated into small fragments, containing bone and bone
marrow, using bone cutters. Total RNA was extracted as
described previously [35,41]. Briefly, bone fragments were
placed in 4 mol/l guanidinium thiocyanate solution and homog-
enized using an Ultra-Turrax (TP 18–10; Janke & Kunkel, IKA-
WERK, Staufen, Germany), and the mixture was clarified by
centrifugation (1,000 × g for 5 min). After addition of 0.1 vol
of 2 mol/l sodium acetate (pH 4.0), the mixture was vortexed
and the RNA extracted with 1 vol of phenol and 0.2 vol of chlo-
roform/isoamylalcohol (49:1). Total RNA was precipitated with
isopropanol, resuspended in 1 × 10 mmol/l Tris-HCl/1 mmol/
l EDTA containing 0.1 vol of 3 mol/l sodium acetate (pH 5.2)
and then re-extracted with 0.5 vol phenol, followed by 0.5 vol
chloroform/isoamylalcohol. The RNA was then precipitated
with 3 vol of 4 mol/l sodium acetate (pH 7.0), to remove con-
taminating proteoglycans, at -20°C overnight. Total RNA was
recovered by centrifugation, washed with 75% ethanol, air
dried, dissolved in diethylpyrocarbonate-treated water, and
stored at -80°C until further use. RNA concentration and purity
(260/280 absorbance ratio) were determined by spectropho-
tometry. RNA integrity was confirmed by visualization on ethid-
ium bromide stained 1% weight/vol agarose-formaldehyde
gels.
Microarray
RNA was further purified using RNeasy columns (Qiagen,
Hilden, Germany), in accordance with the manufacturer's
instructions. RNA (5 μg) was amplified using a Message Amp
II kit (Ambion, Austin, TX, USA) with indirect, amino allyl medi-
ated incorporation of either Cy3 or Cy5 dyes (Amersham Bio-
sciences, Piscataway, NJ, USA), in accordance with the
manufacturer's instructions. A Compugen Human 19K-oligo
library (Jamesburg, NJ, USA) spotted onto Corning glass
slides (Lowell, MA, USA) by the Adelaide Microarray facility
(AMF) was used in this study. The Compugen human oligo
library consisted of 17,260 oligonucleotide 65-mers each rep-
resenting a single human gene. The slides were interrogated
by competitive hybridization with 5 μg each of Cy3 and Cy5
labelled pairs of OA-control, OA-OP, or OP-control amplified
RNA samples. The sample pairs used in the microarray analy-
sis are listed in Table 1. Sample pairs were age-matched as
closely as possible.
A biological dye-swap strategy was employed rather than a
replicate dye swap strategy. This involved swapping of Cy3
and Cy5 labelling of the samples in each pair for each group
of paired samples to balance for potential dye incorporation
and signal intensity bias. It also reduced the number of slides
required for the experiment and maximized the statistical
power of the experiment with regard to analyzing the biological
differences between samples.
Hybridization and washing of slides was carried out according
to methods described on the AMF website [42]. The micro-
array slides were scanned twice at slightly different PMT
voltage using a GenePix 4000B Scanner driven by GenePix
Pro 4.0 (Axon Instruments, Foster City, CA, USA). All analyses
were performed using the statistical programming and graph-
ics environment R [43]. The 'SPOT' software package [44]
was used to identify spots using the adaptive segmentation
method and subtract backgrounds utilizing the morphological
opening approach [45,46]. Data analysis was performed in R
using Bioconductor [47]. The Loess print tip method was used
to correct for dye bias and intensity within each group of adja-
cent spots printed by one pin [48]. Linear modelling was per-
formed using the linear models for microarray analysis
(LIMMA) package of Bioconductor [49]. Differentially
expressed genes were ranked on moderated t statistics, and
those with t scores above 3 were followed up further. ThePage 3 of 21
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Control versus OA versus OP sample microarray comparisons
Sample pair
Slide GEO accession 
number
ID Status Age (years) ID Status Age (years)
1 GSM207548 1 CTL 85 12 OA 83
2 GSM207549 2 CTL 83 13 OA 82
3 GSM207810 2 CTL 83 14 OA 82
4 GSM207811 3 CTL 72 15 OA 78
5 GSM207550 4 CTL 72 16 OA 77
6 GSM207812 5 CTL 68 21 OA 68
7 GSM207552 6 CTL 68 17 OA 66
8 GSM207553 7 CTL 60 18 OA 60
9 GSM207554 8 CTL 56 19 OA 56
10 GSM207555 9 CTL 43 20 OA 49
11 GSM208577 37 CTL 85 47 OA 85
12 GSM208575 38 CTL 73 48 OA 77
13 GSM208578 39 CTL 71 49 OA 73
14 GSM208576 40 CTL 71 50 OA 70
15 GSM208579 41 CTL 70 51 OA 69
16 GSM208583 42 CTL 69 52 OA 63
17 GSM208580 43 CTL 64 53 OA 63
18 GSM208582 44 CTL 60 54 OA 62
19 GSM208581 45 CTL 57 55 OA 57
20 GSM208584 46 CTL 50 56 OA 50
21 GSM207805 26 OP 91 22 OA 87
22 GSM207813 27 OP 87 12 OA 83
23 GSM207803 34 OP 87 13 OA 82
24 GSM207804 28 OP 84 23 OA 79
25 GSM207808 29 OP 81 24 OA 78
26 GSM207806 35 OP 78 15 OA 78
27 GSM207807 36 OP 78 16 OA 77
28 GSM207556 35 OP 78 25 OA 73
29 GSM208574 32 OP 74 21 OA 68
30 GSM207809 33 OP 74 17 OA 66
32 GSM207798 2 CTL 83 27 OP 87
33 GSM207557 2 CTL 83 34 OP 87
34 GSM207796 10 CTL 83 28 OP 84
35 GSM207797 11 CTL 74 29 OP 81
36 GSM207799 4 CTL 72 36 OP 78
37 GSM207800 3 CTL 72 30 OP 77
38 GSM207551 3 CTL 72 31 OP 75
39 GSM207801 5 CTL 68 32 OP 74
40 GSM207802 6 CTL 68 33 OP 74
'Slide' indicates the microarray slide comparison. Slides 1 to 10 are control (CTL)-osteoarthritis (OA) female sample pairs, slides 11 to 20 are 
CTL-OA male sample pairs, slides 21 to 30 are OA-osteoporosis (OP) female sample pairs and slides 32 to 40 are CTL-OP female sample pairs. 
GEO, Gene Expression Omnibus; ID, individual/sample.Page 4 of 21
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change to its standard error. Because there is no consensus
on appropriate adjustment of P values in the context of micro-
arrays, genes of interest were chosen based on a combination
of statistical and biological indicators. Microarray data have
been deposited in the Gene Expression Omnibus [50] and are
accessible through Gene Expression Omnibus series number
GSE8406.
Real-time PCR
First-strand reverse transcription cDNA synthesis was per-
formed on 1 μg amplified RNA from each sample using a first-
strand cDNA synthesis kit with Superscript II (Invitrogen,
Carlsbad, CA, USA) and 250 ng random hexamer primer
(Geneworks, Adelaide, SA, Australia), in accordance with the
manufacturer's instructions. Template cDNA (1 μl of 1/100
dilution of cDNA) was amplified using iQ SYBR Green Super-
mix (BioRad, Hercules, CA, USA) on a Rotor-Gene thermocy-
cler (Corbett Research, Mortlake, NSW, Australia). The
reactions were incubated at 94°C for 10 min for 1 cycle, and
then 94°C (20 seconds), 60°C, or 65°C (ADAMTS4 and
MMP25 only; 20 seconds) and 72°C (30 seconds) for 40
cycles. This set of cycles was followed by an additional exten-
sion step at 72°C for 5 minutes. All PCR reactions were vali-
dated by the presence of a single peak in the melt curve
analysis, and amplification of a single specific product was fur-
Table 2
GenBank accession numbers and primer sequences
Gene/primer (GenBank accession number) Forward Reverse
GAPDH (NM_002046) ACCCAGAAGACTGTGGATGG CAGTGAGCTTCCCGTTCAG
ADAMTS4 (NM_005099) GGCTACTACTATGTGCTGGAGC TCCGCACACCATGCACTTGTCA
ADM (NM_001124) GGATGAAGCTGGTTTCCGTC GACTCAGAGCCCACTTATTC
ADFP (NM_001122) GTTGCCAATACCTATGCCTG CAGTAGTCGTCACAGCATCT
CD14 (NM_000591) GAGGTTCGGAAGACTTATCG ATCTTCATCGTCCAGCTCAC
COL4A1 (NM_001845) TAGAGAGGAGCGAGATGTTC GTGACATTAGCTGAGTCAGG
CTNNB1 (NM_001904) GGTGCTATCTGTCTGCTCTAGT GACGTTGACTTGGATCTGTCAGG
FST (NM_006350) GGCAAGATGTAAAGAGCAGC CATTATTGGTCTGGTCCACC
GADD45B (NM_015675) TTGCAACATGACGCTGGAAG CATTCATCAACTTGGCCGAC
IBSP (NM_004967) CAATCCAGCTTCCCAAGAAG CTTCTGCTTCGCTTTCTTCG
INHBA (NM_002192) GAACTTATGGAGCAGACCTC TGCCTTCCTTGGAAATCTCG
INSIG1 (NM_005542) TGTATCGACAGTCACCTCGGA GGACAGCTGGACATTATTGGC
ITGB2 (NM_000211)) AAGTGACGCTTTACCTGCGA CCTGAGGTCATCAAGCATGG
KLF6 (NM_001300) TGTGCAGCATCTTCCAGGAG AACGTTCCAGCTCTAGGCAG
MEPE (NM_020203) GCAAAGCTGTGTGGAAGAGCAGA CCCTTATTCTCACTGGCTTCAG
MMP25 (NM_004142) ATGTCACCGTCAGCAACGCA CGGTCTTGATGCTGTTCTTG
MT2A (NM_005953) GCAAATGCACCTCCTGCAAG GTGGAAGTCGCGTTCTTTAC
NHERF1 (NM_004252) TCACCAATGGGGAGATACAG GTCTTGGGAATTCAGCTCCT
PTEN (NM_000314) AAGACAAAGCCAACCGATAC GAAGTTGAACTGCTAGCCTC
RUNX2 (NM_004348) TGATGACACTGCCACCTCTG GGGATGAAATGCTTGGGAAC
S100A4 (NM_002961) GTCAGAACTAAAGGAGCTGC TGTTGCTGTCCAAGTTGCTC
SMAD3 (NM_005902) TTCAACAACCAGGAGTTCGC TACTGGTCACAGTA
STC1 (NM_003155) CCTGTGACACAGATGGGATG GAATGGCGAGGAAGACCTTG
TIMP4 (NM_003256) TTGACTGGTCAGGTCCTCAGT GGTACTGTGTAGCAGGTGGT
TWIST1 (NM_000474) TCAGCAGGGCCGGAGACCTAGAT GTCTGGGAATCACTGTCCAC
WNT5B (AY009399) ACCCTACTCTGGAAACTGTC TAAACATCTCGGGTCTCTGC
'Slide' indicates the microarray slide comparison. Slides 1 to 10 are control (CTL)-osteoarthritis (OA) female sample pairs, slides 11 to 20 are 
CTL-OA male sample pairs, slides 21 to 30 are OA-osteoporosis (OP) female sample pairs and slides 32 to 40 are CTL-OP female sample pairs. 
GEO, Gene Expression Omnibus; ID, individual/sample.Page 5 of 21
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ose gel. Primers were designed for each gene that primed in
separate exons and spanned at least one intron to avoid con-
taminating amplification from genomic DNA. Primers were
obtained from Geneworks. Amplicons were designed to be in
the 100 to 200 base pairs size range. GenBank accession
numbers for gene sequences and primer sequences are pro-
vided in Table 2. Real-time PCR validation was carried out
using the 2-ΔΔCT method [51]. Reactions were performed in
duplicate. Normalized gene expression values for each gene
based on cycle threshold (CT) values for each of the genes
and the housekeeping gene GAPDH were generated. Mean ±
standard deviation (SD) values were generated from eight
samples from each group of either OA or control samples
tested.
Statistical analysis
The statistical significance of the differences between the
means of the OA and control or OP gene expression values
was determined using Student's t-test. The critical value for
significance was chosen as P < 0.05.
Results
Microarray analysis of OA, control and OP bone samples
This study used Compugen human 19K-oligo human micro-
array slides to compare the gene expression profiles of OA,
control and OP bone samples, with the aim being to identify
altered gene expression in OA bone. Microarray analysis was
conducted in four sets of samples (39 comparisons in total),
comprising 10 OA-control female sample pairs, 10 OA-control
male sample pairs, 10 OA-OP female sample pairs and 9 OP-
control female sample pairs. Samples from individuals with a
range of ages were analyzed in each group, but with sample
pairs age-matched as closely as possible (Table 1). Bayesian
statistical analysis was carried out using LIMMA to identify sta-
tistically significant differentially expressed genes between
OA, control and OP bone. Log odds score versus log2 fold
change volcano plots of differentially expressed genes from
each of the four groups of sample pair comparisons are shown
in Figure 1. The log odds (or B statistic) score is the log odds
that that gene is differentially expressed. The log2 fold change
represents the fold change in expression of the gene. Small
levels of differential expression (ranging from 0.38-fold to
2.83-fold change in expression) were detected, with several
hundred differentially expressed genes present in each group-
ing, with t scores above 6. The moderated t-statistic score is
based on the ratio of the log2 fold change to its standard error.
Identification and functional classification of top-
ranking differentially expressed genes in OA bone
By comparing the lists of ranked differentially expressed genes
from each of the four initial groupings, we were able to identify
a group of differentially expressed genes that was more likely
to be associated with the OA disease process. This group of
genes was assembled by filtering out genes that were similarly
regulated between OA-control and OP-control samples in
order to remove genes that were more likely to be differentially
expressed because of potential differences caused by sourc-
ing bone at surgery versus autopsy. Because there were also
very few significant differences in gene expression between
the male and female OA-control groups, these data were com-
bined because it strengthened the statistical significance of
the genes identified as differentially expressed. Using these
selection processes, several hundred genes from each initial
grouping was reduced to a list of 150 differentially expressed
genes in OA bone with t scores above 4.
Gene function and pathway analyses were carried out by
searching the National Centre for Biotechnology Information
database [52] and by using various analysis programs includ-
ing OntoExpress [53] and Gostat [54]. We were able to iden-
tify a group of 62 top-ranking OA differentially expressed
genes from within the initial list of 150 genes, which have
known or suspected roles (direct or indirect via angiogenesis)
in influencing bone development or bone remodelling (Table
3). For many of the genes both osteogenic and angiogenic
roles have been described. In addition, a subset of these
genes, particularly those that encode secreted, cell surface
and extracellular matrix molecules, also have potential
chondrogenic functions, consistent with the proposal that an
altered OA subchondral bone microenvironment could inter-
fere with cartilage metabolism.
Although many of the genes identified in this analysis have
pleiotropic effects in bone and other tissues, it was of interest
that many of the top-ranking differentially expressed genes in
OA bone have known or suspected roles in osteoblast and
osteocyte differentiation and function. These genes included
ADAMTS4, ADM, GADD45B, IBSP, MMP25, MT2A, STC1,
MEPE, TWIST1, IGFBP3, S100A4, AKT3 and COL4A1.
There was also a group of differentially expressed genes in OA
bone that have known or potential roles in osteoclast function,
such as the previously mentioned osteoblast-related genes
ADAMTS4, GADD45B, STC1 and IGFB3, as well as
ADAM8, CCR2, CSTA, RAC2, CRYAB and CYP1B. Func-
tionally, within the list of genes given in Table 3, there are
genes encoding secreted molecules (ADM, ANGPTL4,
STC1, CORT, IGFBP3 and MIF), cell surface molecules
(SELL, ICAM3, SELP, CRIM1, CLECSF6, CLECSF2, CCR2
and SLC14A1), intracellular signalling molecules (RAB20,
YWHAG, RAC2, NHERF1, GNA11 and SNX9), protein
kinases (AKT3 and PRKCD), calcium and metal ion binding
proteins (S100A4, S100A6, MT1L, MT2A and MT1G), tran-
scription factors (TWIST1, FMR2, KLF6, NR4A2 and DEC1),
and both enzymatic (ADAMTS4, MMP25, ADAM8, TIMP4,
GALNT4 and CTSG) and structural (TGFBI, IBSP, MEPE,
MFAP3L and COL4A1) extracellular matrix molecules.
Because of the small absolute differences in gene expression
between the bone tissue samples, real-time PCR was used toPage 6 of 21
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tified by the microarray analysis of OA, control and OP bone.
The real-time PCR results (depicted as fold differential
expression) are shown alongside the microarray results in
Table 3. In total, the differential expression levels of 20 genes
were examined using real-time PCR. Results for 16 genes
reached statistical significance (P < 0.01) for differential
expression between OA and control bone. The differential
expression of four genes (TGFBI, S100A6, SLC14A1 and
SNX9) could not be confirmed. The female control samples 1–
8 (age range 56 to 85 years, mean [ ± SD] age 70.5 ± 10
years) and female OA samples 12–19 (age range 56 to 83
years; mean age 73 ± 10.8 years) were used to confirm the
microarray data by real-time PCR (Table 1). The mean age of
the OA group did not differ significantly from that in the control
group. Interestingly, although the microarray expression ratios
were quite small (ranging from 0.62-fold change to 1.47-fold
change in expression), the fold difference in expression identi-
fied using the real-time PCR reactions was significantly
greater in most cases (ranging from 0.08-fold change to 2.6-
fold change in expression). This probably reflects differences
in sensitivity between the two techniques [55,56]. The differ-
ence is probably also accentuated by the competitive pair-
wise comparison of samples used by the microarray platform
in this study compared with the individual gene/GAPDH CT
expression ratio values generated using real-time PCR.
Encouragingly, there was a high confirmation rate with the
real-time PCR and consistency between the microarray and
PCR detection of expression ratio differences for each of the
genes analyzed, suggesting that the majority of the genes
identified by the microarray are bona fide differentially
expressed genes in OA bone.
Altered expression of WNT and TGF-β/BMP signalling 
pathway component and target genes in OA bone
A significant number of the top-ranking differentially expressed
genes in OA bone were identified as WNT signalling pathway
targets (Table 3). WNT targets included upregulated genes
Figure 1
Bayesian statistical analysis of differentially expressed genes using LIMMA. Log odds (LOD) score versus log2 fold change volcano plots of differen-
tially expressed genes from each of the four groups of sample pair comparisons. CTL, control; LIMMA, linear models for microarray analysis; OA, 
osteoarthritis; OP, osteoporosis.Page 7 of 21
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Differentially expressed genes in OA bone with roles in osteogenesis, angiogenesis and chondrogenesis
Real-time PCR
Rank GenBank Role Cell type Pathway Symbol Name t OA/CTL t OA/OP Symbol OA/CTL
ADAMTS4 0.11
2 NM_001124 A, B, C OB, OC, 
OS, CB
TGF-β/BMP ADM Adrenomedullin -12.620 -7.904 ADM 0.09
3 NM_002450 B OB MT1L Metallothionein 1L -8.342 -6.843
4 NM_016109 A WNT ANGPTL4 Angiopoietin-like 4 -6.165 -8.052
5 NM_015675 B OB, OC, 
CB
TGF-β/BMP GADD45B Growth arrest and DNA-
damage-inducible, beta
-8.102 -5.985 GADD45B 0.15
7 NM_000358 A, B TGF-β/BMP TGF-BI Transforming growth factor, 
beta-induced
-6.915 -5.741
9 NM_017817 RAB20 RAB20, member RAS 
oncogene family
-5.147 -6.982
10 NM_004967 B, C OB, CB WNT & TGF-β/BMP IBSP Integrin-binding sialoprotein -5.088 -5.865 IBSP 0.25
12 AB014526 B OB MFAP3L Microfibrillar-associated 
protein 3-like
5.284 4.983
13 NM_004142 A, B, C OB, OC, 
CB
WNT MMP25 Matrix metalloproteinase 25 4.942 7.183 MMP25 2.60
15 NM_002025 B TGF-β/BMP FMR2 Fragile × mental retardation 2 4.915 4.851
18 NM_005953 B OB MT2A Metallothionein 2A -4.638 -7.071 MT2A 0.18
20 NM_013258 A, B M OC PYCARD PYD and CARD domain 
containing
6.567 4.355
21 NM_014467 SRPX2 Sushi-repeat-containing 
protein, X-linked 2
-4.333 -4.918
22 NM_003155 A, B, C OB, OC, 
CB
STC1 Stanniocalcin 1 -6.656 -4.274 STC1 0.16
23 NM_001109 B OC ADAM8 A disintegrin and 
metalloproteinase domain 8
5.426 4.269
24 NM_020203 B OB, OS TGF-β/BMP MEPE Matrix, extracellular 
phosphoglycoprotein with 
ASARM motif
-5.036 -4.263 MEPE 0.11
28 S68954 B OB MT1G Metallothionein 1G -4.202 -7.630
29 AK026438 B OB GALNT4 Polypeptide N-
acetylgalactosaminyltransfera
se 4
5.259 4.195
30 NM_000474 B OB WNT TWIST1 Twist homolog 1 -4.194 -4.910 TWIST1 0.31
33 NM_000655 B M SELL Selectin L 4.852 4.179
36 NM_002341 A, B, C OB, CB LTB Lymphotoxin beta 4.465 4.086
37 NM_003226 A TFF3 Trefoil factor 3 4.080 4.074
42 NM_000607 B M ORM1 Orosomucoid 1 4.284 3.982
46 NM_005542 INSIG1 Insulin induced gene 1 -7.756 -3.878 INSIG1 0.55
49 NM_001302 B M CORT Cortistatin -6.713 -3.843
52 NM_000598 A, B, C OB, OC, 
CB
WNT & TGF-β/BMP IGFBP3 Insulin-like growth factor 
binding protein 3
-3.772 -3.893
54 NM_012479 A, B OB YWHAG Tyrosine 3-/tryptophan 5-
monooxygenase activation 
protein, gamma
-3.759 -5.355
59 NM_014624 B OB WNT S100A6 S100 calcium binding protein 
A6
8.214 3.710
61 NM_006732 A, B OB FOSB FBJ murine osteosarcoma 
viral oncogene homolog B
3.682 3.926
64 NM_002961 A, B OB WNT S100A4 S100 calcium binding protein 
A4
4.407 3.596 S100A4 2.43
65 NM_016184 B M CLECSF6 C-type lectin domain family 4, 
member A
4.575 3.594
68 NM_006184 B NUCB1 Nucleobindin 1 -3.551 -5.513Page 8 of 21
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Available online http://arthritis-research.com/content/9/5/R100such as MMP25 and S100A4, and downregulated genes
such as IBSP, TWIST1 and TIMP4. The altered expression of
these genes suggests that WNT signalling may be perturbed
in the OA bone microenvironment. This was apparently borne
out by closer examination of the extended list of differentially
expressed genes in OA bone, which revealed further WNT sig-
nalling pathway components and modulators such as
WNT5B, FZD3, SFRP5, APC, AXIN2, PTEN and NHERF1.
These genes, and additional WNT target genes such as
CD14, APOE, ID1, IL6, FST and RUNX2, are listed in Table
69 NM_001300 A WNT & TGF-β/BMP KLF6 Kruppel-like factor 6 -4.047 -3.544 KLF6 0.41
70 NM_004864 A, B OB, CB TGF-β/BMP GDF15 Growth differentiation factor 
15
-3.541 -4.269
73 U79271 B OB, OC WNT AKT3 V-akt murine thymoma viral 
oncogene homolog 3
3.507 4.876
76 S83282 A, B OB, OC MIF Macrophage migration 
inhibitory factor
-3.654 -3.496
81 NM_005213 B OC CSTA Cystatin A 4.450 3.447
82 NM_000647 A, B M OC CCR2 Chemokine (C-C motif) 
receptor 2
7.277 3.446
85 NM_001911 A CTSG Cathepsin G 8.474 3.411
87 NM_001122 WNT ADFP Adipose differentiation-
related protein
-3.368 -10.219 ADFP 0.21
92 NM_006254 A, B OB PRKCD Protein kinase C, delta 5.549 3.319
94 NM_002162 A ICAM3 Intercellular adhesion 
molecule 3
3.304 5.798
95 NM_001885 B OB, OC CRYAB Crystallin, alpha B -3.296 -7.616
96 D17152 A WNT SOD2 superoxide dismutase 2 -6.347 -3.278
102 NM_003256 A WNT TIMP4 Tissue inhibitor of 
metalloproteinase 4
-6.319 -3.250 TIMP4 0.08
105 NM_000698 M ALOX5 Arachidonate 5-lipoxygenase 3.229 4.736
106 NM_014029 B OC RAC2 Rho family, small GTP binding 
protein Rac2
3.227 5.325
108 NM_003670 B, C OB, CB TGF-β/BMP DEC1 Differentially expressed in 
chondrocytes 1
-3.203 -3.783
109 NM_002067 B OB GNA11 Guanine nucleotide binding 
protein, alpha 11
-4.353 -3.202
115 AF263545 B OB SLC14A1 Solute carrier family 14, 
member 1
3.163 5.759
120 NM_005127 B M CLECSF2 C-type lectin domain family 2, 
member B
-7.330 -3.141
123 NM_004252 B WNT NHERF1 Sodium/Hydrogen exchanger 
regulatory factor 1
5.280 3.138 NHERF1 1.71
124 NM_006186 B OB NR4A2 Nuclear receptor subfamily 4, 
group A, member 2
-3.128 -3.354
133 NM_000104 B OC CYP1B1 Cytochrome P450, family 1, 
subfamily B, 1
-3.075 -5.148
136 NM_003005 B SELP Selectin P 8.740 3.066
139 NM_004334 B OC BST1 Bone marrow stromal cell 
antigen 1 (CD157)
3.037 3.601
141 AK023619 A CRIM1 Cysteine-rich motor neuron 1 -3.043 -3.271
143 NM_013332 A WNT HIG2 Hypoxia-inducible protein 2 -6.019 -3.035
144 NM_001845 A, B TGF-β/BMP COL4A1 Collagen, type IV, alpha 1 -3.028 -8.960 COL4A1 0.57
146 NM_016224 A, B OB WNT SNX9 Sorting nexin 9 -3.025 -6.086
Rank' indicates the ranking within the top 150 differentially expressed genes in osteoarthritis (OA) bone compared with control (CTL) and 
osteoporosis (OP) bone. 'Role' indicates the known or suspected role of the gene: A, angiogenic; B, osteogenic; and C, chondrogenic. 'Cell 
type' indicates the cell type that the gene is expressed in or affects: OB, osteoblast, OC, osteoclast, OS, osteocyte, CB, chondroblast, or M, 
monocyte. 't OA/CTL' is the t score of OA compared with CTL differential expression of gene: a positive value indicates upregulation in OA 
and a negative one indicates downregulation in OA. 't OA/OP' is the t score of OA compared with OP differential expression of gene: a 
positive value indicates upregulation in OA and a negative one indicates downregulation in OA. The moderated t-statistic score is based on 
the ratio of the log2 fold change to its standard error. 'OA/CTL' under 'Real-time PCR' indicates the fold change in gene expression expressed 
as ratio of OA to CTL.
Table 3 (Continued)
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WNT and TGF-β/BMP signalling pathway components and target genes differentially expressed in OA bone
Real-time PCR
GenBank Role Cell type Symbol Name t OA/CTL t OA/OP Symbol OA/CTL
WNT pathway components and modulators
AY009399 B, C OB, OC, CB WNT5B Wingless-type MMTV integration site family, 
member 5B
3.719 0.717 WNT5B 2.52
NM_002332 A, B, C OB, OC, CB LRP1 Low density lipoprotein-related protein 1 3.062 -7.071
NM_002333 LRP3 Low density lipoprotein-related protein 3 5.950 1.146
NM_017412 FZD3 Frizzled homolog 3 -3.677 0.835
AF086500 FZD8 Frizzled homolog 8 3.024 -1.557
NM_003015 SFRP5 Secreted frizzled-related protein 5 -4.338 1.154
NM_004655 AXIN2 Axin 2 -3.123 2.490
NM_000038 APC Adenomatosis polyposis coli -5.171 1.155
AK023892 DAAM1 Dishevelled associated activator of 
morphogenesis 1
-6.704 2.850
NM_000314 A, B OB, OC PTEN Phosphatase and tensin homolog -5.288 -0.216 PTEN 0.30
AF028823 TIP1 Tax interaction protein 1 5.057 -5.674
AB006630 TCF20 Transcription factor 20 8.559 2.719
AK026898 B M FOXP1 Forkhead box P1 -5.122 1.761
WNT inducible/target genes
NM_000591 B OB, OC, M CD14 CD14 antigen 5.965 -7.036 CD14 3.47
NM_004039 A, B OB, OC, M ANXA2 Annexin A2 5.716 -7.601
NM_000211 B OC ITGB2 Integrin, beta 2 (CD18) 6.104 -1.243 ITGB2 2.95
NM_018456 EAF2 ELL associated factor 2 6.450 0.884
NM_000041 B OB, M APOE Apolipoprotein E 6.896 -2.391
AB012643 B OB ALPL Alkaline phosphatase, liver/bone/kidney -5.942 -1.213
NM_002229 B OB JUNB Jun B proto-oncogene 5.053 -3.804
NM_003377 A, B VEGFB Vascular endothelial growth factor B 3.238 -3.772
NM_005429 A, B VEGFC Vascular endothelial growth factor C 5.304 0.473
NM_000963 B OB PTGS2 Prostaglandin-endoperoxide synthase 2 4.346 -0.842
NM_005194 B OB CEBPB CCAAT/enhancer binding protein, beta 4.273 -4.092
AL353944 A, B OB ID1 Inhibitor of DNA binding 1 3.923 -1.996
NM_000900 B OB MGP Matrix Gla protein 2.791 -3.073
M14584 A, B, C OB, OC, CB IL6 Interleukin 6 2.589 -3.612
NM_006350 B, C OB, CB FST Follistatin -2.137 -7.912 FST 0.38
AL353944 B OB RUNX2 Runt-related transcription factor 2 1.611 1.050 RUNX2 2.07
TGF-β/BMP pathway components and modulators
M38449 A, B, C OB, OC, CB TGFB1 Transforming growth factor, beta 1 2.739 3.054
AK021486 B, C OB, CB BMP5 Bone morphogenetic protein 5 -10.314 -2.263
NM_002192 A, B, C OB, OC, CB INHBA Inhibin, beta A -7.699 -0.389 INHBA 0.31
NM_006350 B, C OB, CB FST Follistatin -2.137 -7.912 FST 0.38Page 10 of 21
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scores above 3) in general were not as pronounced as that
seen for the target genes identified from within the top-ranking
150 genes.
In addition, a significant number of TGF-β/BMP signalling
pathway target genes were identified as being differentially
expressed in OA bone (Table 3). TGF-β/BMP signalling path-
way targets included downregulated genes such as
ADAMTS4, ADM, GADD45B, MEPE and COL4A1. The
altered expression of these genes also suggests that TGF-β/
BMP signalling may be perturbed in the OA bone microenvi-
ronment. Additional evidence for this was that genes for TGF-
β/BMP signalling pathway components and modulators, such
as TGFB1, BMP5, INHBA, SMAD3 and FST, were also iden-
tified in the extended list of differentially expressed genes in
OA bone. These genes, and additional TGF-β/BMP target
genes identified, such as COL1A2, GSN, DMP1 and ITGB2,
are listed in Table 4. The differences in expression of this
group of genes (t scores above 3) was not as pronounced as
the target genes identified from within the top-ranking 150
genes.
Like the top-ranking list of 150 differentially expressed genes
in OA bone, many of the WNT and TGF-β/BMP signalling
pathway related genes identified in Table 4 also have known
or suspected roles in either osteoblast (WNT5B, PTEN,
CD14, SMAD3, RUNX2, ID1, HDAC4, TGFB1, BMP5,
NM_004612 B TGFBR1 Transforming growth factor, beta receptor I -4.915 1.049
NM_000118 A ENG Endoglin 4.131 -2.461
NM_001105 B OB ACVR1 Activin A receptor, type I 3.791 -0.941
NM_003573 LTBP4 Latent transforming growth factor beta 
binding protein 4
-4.060 2.623
NM_005902 A, B OB SMAD3 SMAD, mothers against DPP homolog 3 4.119 -3.582 SMAD3 2.64
NM_005359 A, B OB SMAD4 SMAD, mothers against DPP homolog 4 3.957 0.156
NM_002165 A, B OB ID1 Inhibitor of DNA binding 1 3.923 -1.996
NM_002229 B OB JUNB Jun B proto-oncogene 5.053 -3.804
NM_005655 B OB KLF10 Kruppel-like factor 10 4.443 -4.449
NM_006037 B OB HDAC4 Histone deacetylase 4 8.475 2.468
NM_000168 B OB GLI3 GLI-Kruppel family member GLI3 -4.675 -0.298
AL353944 B OB RUNX2 Runt-related transcription factor 2 1.611 1.050 RUNX2 2.07
TGF-β/BMP inducible/target genes
AK001052 B OB FGFR1 Fibroblast growth factor receptor 1 4.234 1.993
NM_001553 A IGFBP7 Insulin-like growth factor binding protein 7 5.137 -6.302
NM_000211 B OC ITGB2 Integrin, beta 2 (CD18) 6.104 -1.243 ITGB2 2.95
AK001060 B, C OB, CB DCN Decorin -6.325 2.628
NM_000177 B OC GSN Gelsolin 4.725 -2.387
X55525 B OB COL1A2 Collagen, type I, alpha 2 5.538 -3.633
NM_003118 A, B OB SPARC Secreted protein, acidic, cysteine-rich 3.188 -1.844
NM_004407 B OB, OS DMP1 Dentin matrix acidic phosphoprotein -3.523 -1.397
NM_001831 A, B CLU Clusterin 4.803 -2.030
Not represented on Compugen human 19K microarray
NM_001904 A, B OB, OC CTNNB1 Catenin beta 1 CTNNB1 2.38
'Role' indicates the known or suspected role of the gene: A, angiogenic; B, osteogenic; and C, chondrogenic. 'Cell type' indicates the cell type 
that the gene is expressed in or affects: OB, osteoblast, OC, osteoclast, OS, osteocyte, CB, chondroblast, or M, monocyte. 't OA/CTL' is the t 
score of osteoarthritis (OA) compared with control (CTL) differential expression of gene: a positive value indicates upregulation in OA and a 
negative one indicates downregulation in OA. 't OA/OP' is the t score of OA compared with osteoporosis (OP) differential expression of gene: a 
positive value indicates upregulation in OA and a negative one indicates downregulation in OA. The moderated t-statistic score is based on the 
ratio of the log2 fold change to its standard error. 'OA/CTL' under 'Real-time PCR' indicates the fold change in gene expression expressed as ratio 
of OA to CTL. BMP, bone morphogenic protein; TGF, transforming growth factor.
Table 4 (Continued)
WNT and TGF-β/BMP signalling pathway components and target genes differentially expressed in OA bonePage 11 of 21
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 9 No 5    Hopwood et al.INHBA, DMP1 and FST) or osteoclast (CD14, PTEN,
FOXP1, ANXA2, ITGB2, IL6 and GSN) differentiation and
function.
The differential expression of a selection of these WNT and
TGF-β/BMP signalling pathway component and target genes
was confirmed by real-time PCR. In total, the differential
expression of 11 genes was examined by real-time PCR (Table
4). The differential expression of two genes (LRP1 and
IGFBP7) could not be confirmed. However, results for the
other nine genes reached statistical significance (P < 0.01) for
differential expression between OA and control bone.
CTNNB1 was assayed directly by real-time PCR because it
was not represented on the Compugen H19K library. Seven of
the remaining nine genes (with FST and RUNX2 being the
exceptions) were represented in the top-ranking 300 genes
differentially regulated in OA bone. These genes were tested,
like those listed in Table 3, using female control samples 1 to
8 and female OA samples 12 to 19 (Table 1). The range of fold
difference in expression identified by the real-time PCR reac-
tions was slightly smaller (ranging from 0.3-fold change to
3.47-fold change in expression) than for the group of genes
tested from the top ranking 150 genes in Table 3.
Identification of differentially expressed OA genes 
between females and males
There is a higher incidence of primary hip OA in females than
in males [1], and we were interested in identifying differences
in gene expression between females and males that may con-
tribute to this disparity. Therefore, we tested for differences
between the OA-control female and male microarray datasets.
Genes with the greatest difference in expression between
females and males in the OA-control microarray comparisons
are listed in Table 5. There were very few significant differ-
ences in gene expression between females and males. How-
ever, approximately 50 genes with t scores above 3, which
included the top-ranking 20 genes with t scores above 4, were
identified as being differentially expressed between females
and males. Interestingly, a significant proportion of these
genes have known or suspected roles in osteoclast-lineage
cells and osteoclasts (GSN, PTK9, VCAM1, ITGB2, GRN,
ANXA2, PDE4A and FOXP1). There are also genes with
known roles in osteoblasts (LTF, DF, PRKCG and TGFB1). A
number of the highest ranking differentially expressed genes
between females and males in OA bone also involve WNT sig-
nalling pathway components, including WNT5B, along with
the EAF2 and CTBP2 genes, which encode transcription fac-
tors that are involved in mediating WNT signalling.
The differential expressions of WNT5B and ITGB2 (along with
MMP25) between females and males in OA bone were con-
firmed by real-time PCR (Figure 2). MMP25 was not originally
identified as being differentially expressed between females
and males in OA bone by microarray analysis. WNT5B, ITGB2
and MMP25 were all found to be differentially expressed only
in females, and not in males, between OA and control bone.
The OA/control ratios of expression for the WNT5B gene
were 2.52 in female samples (P < 0.01) and 0.92 in male sam-
ples (P = 0.7486); those for the ITGB2 gene were 2.95 (P <
0.01) and 1.35 (P = 0.1173), respectively; and those for the
MMP25 gene were 2.60 (P < 0.01) and 1.01 (P = 0.4748),
respectively. There was also a significant difference in the total
expression levels of these three genes between females and
males, being approximately 6-fold, 14-fold and 23-fold higher
for WNT5B, MMP25 and ITGB2, respectively, in females than
in males in OA bone. Thirteen other genes (ADAM8, ADM,
ADAMTS4, ADFP, CD14, COL14A1, GADD45B, LRP1,
S100A4, SMAD3, TGFBI, TIMP4 and TWIST1) were also
tested for differential expression between females and males
in OA bone, but none of these was found to be differently
expressed (data not shown). Genes were tested using female
control samples 1 to 8 and OA samples 12 to 19 as compared
with male control samples 37 to 44 (age range 60 to 85 years;
mean [ ± SD] age 70.4 ± 7.3 years) and OA samples 47 to 54
(62 to 85 years; 70.3 ± 8 years; Table 1). The mean ages of
the female and male OA groups did not significantly differ from
those of the control groups. Of the other 13 genes examined
by PCR, only SMAD3 had significant differences in total
expression levels between males and females, being approxi-
mately 2-fold higher in males than in females (Figure 2). How-
ever, SMAD3 was similarly differentially regulated between
OA and control bone in both females and males (ratio of OA/
control: 2.64 in females [P < 0.01] and 2.08 in males [P <
0.01]).
Discussion
In this study we identified altered expression of WNT and
TGF-β/BMP signalling pathway component and target genes
in OA bone distal to the disease site (from the IT region of the
proximal femur). This was accomplished by using microarray
analysis to compare gene expression in bone from individuals
with end-stage OA disease and individuals without obvious
OA (control or OP). The genes identified include those with
known or suspected roles in osteoblast, osteocyte and osteo-
clast differentiation and function, as well as angiogenesis, sug-
gesting perturbation of these processes and a role for altered
bone remodelling in OA pathogenesis.
The trabecular bone sampled in this study included all of the
cellular elements of bone, including the bone marrow. This has
provided a 'snapshot' of the gene expression in OA bone, with
contributions from all of the different cells in the bone
microenvironment. Although the specific cell type(s) contribut-
ing to the altered gene expression cannot readily be identified,
osteoblasts and osteocytes, which represent the most abun-
dant cells in the trabecular bone [57], would be expected to
contribute significantly to the altered gene expression meas-
ured. In addition, because we have analyzed bone from end-
stage OA, it is difficult to determine unequivocally that the
altered gene expression detected in the OA bone is causal orPage 12 of 21
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we have avoided secondary pathogenic changes that the
subchondral bone undergoes at the joint as the disease
progresses (such as sclerosis, osteophytes and cysts), which
could confound identification of altered gene expression
potentially responsible for the underlying subchondral bone
remodelling. Therefore, we suggest that the altered gene
expression identified in the IT region from OA bone may be
informative about underlying systemic OA disease mecha-
nisms that also operate at the joint in the subchondral bone.
Table 5
Genes differentially expressed between female and male OA and control bone samples
GenBank Role Cell type Symbol Name t OAF/OAM t OA/CTL t OA/OP
Differentially expressed genes in top 20 regulated genes
NM_000177 B OC GSN Gelsolin 5.983 4.725 -2.387
NM_001078 B OB, OC VCAM1 Vascular cell adhesion molecule 1 5.158 -1.358 -2.377
NM_006764 IFRD2 Interferon-related developmental regulator 2 -5.081 4.274 2.162
NM_018456 EAF2 ELL associated factor 2 4.574 6.450 0.884
NM_002087 B OC GRN Granulin 4.562 11.161 -2.008
NM_000211 B OC ITGB2 Integrin, beta 2 (CD18) 4.378 6.104 -1.243
NM_004203 PKMYT1 Protein kinase, membrane associated tyrosine/
threonine 1
-4.373 -3.375 1.741
NM_001329 CTBP2 C-terminal binding protein 2 -4.339 1.548 4.057
NM_006202 B OB, OC PDE4A Phosphodiesterase 4A -4.131 -1.565 3.337
NM_017845 COMMD8 COMM domain containing 8 4.118 3.264 -0.398
AY009399 B, C OB, OC, CB WNT5B Wingless-type MMTV integration site family, member 
5B
4.107 3.719 0.717
NM_002822 B OC PTK9 PTK9 protein tyrosine kinase 9 4.099 -0.597 -5.894
NM_002343 B OB LTF Lactotransferrin 4.096 4.918 1.882
Additional differentially expressed genes in top 50 regulated genes
NM_005606 A, B OB, OC LGMN Legumain 3.853 9.631 -4.470
NM_015946 A, B, C OB, CB ITGA1 Integrin, alpha 1 3.813 3.904 0.131
NM_004039 B OB, OC ANXA2 Annexin A2 3.754 5.716 -7.601
M14087 A, B OB LGALS1 Lectin, galactoside-binding, soluble, 3.705 4.583 -0.045
NM_006079 A, B OB CITED2 Cbp/p300-interacting transactivator with Glu/Asp-
rich domain 2
3.591 8.580 -1.403
M38449 A, B, C OB, OC, CB TGFB1 Transforming growth factor, beta 1 -3.575 2.739 3.054
Z15114 A, B OB PRKCG Protein kinase C, gamma -3.570 0.018 3.741
NM_003639 B OC IKBKG I kappa B kinase gamma 3.376 6.775 -1.704
AK026898 B OC FOXP1 Forkhead box P1 -3.348 -5.122 1.761
NM_001928 B OB DF D component of complement (adipsin) 3.306 6.851 -0.991
NM_006037 B OB HDAC4 Histone deacetylase 4 3.272 8.475 2.468
NM_001742 B OC CALCR Calcitonin receptor -3.036 0.663 1.800
Not detected by microarray to be differentially regulated between females and males
NM_004142 A, B, C OB, OC, CB MMP25 Matrix metalloproteinase 25 0.237 4.942 7.183
'Role' indicates the known or suspected role of the gene: A, angiogenic; B, osteogenic; and C, chondrogenic. 'Cell type' indicates the cell type that 
the gene is expressed in or affects: OB, osteoblast, OC, osteoclast, OS, osteocyte, or CB, chondroblast. 't OAF/OAM' is the t score of 
osteoarthritis (OA) female compared with OA male differential expression of gene: a postive value indicates upregulation in OA female and a 
negative one indicates downregulation in OA female. 't OA/CTL' is the t score of OA compared with CTL differential expression of gene: a positive 
value indicates upregulation in OA and a negative one indicates downregulation in OA. 't OA/OP' is the t score of OA compared with osteoporosis 
(OP) differential expression of gene: a positive value indicates upregulation in OA and a negative one indicates downregulation in OA. The 
moderated t-statistic score is based on the ratio of the log2 fold change to its standard error.Page 13 of 21
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ing differentially expressed genes in OA bone (Table 3) have
known or suspected roles in osteoblast and osteocyte differ-
entiation and function. (Also see Table 6 for descriptions of the
functions of selected genes: MEPE, IBSP, MT2A, ADM,
STC1, IGFBP3, GADD45B, ADAMTS4, S100A4 and
MMP25.) Significantly, the changes in expression of these
genes as a group suggest altered osteoblast and osteocyte
activity in OA bone, which is consistent with increased bone
volume fraction and under-mineralization previously reported
in OA bone [3,4,11,22-25]. For instance, MEPE (matrix extra-
cellular phosphoglycoprotein), which is highly expressed in
osteoblasts and osteocytes, appears to be an important regu-
lator of bone formation and mineralization. Targeted disruption
of MEPE has been found to result in increased bone formation
and bone mass [58]. MEPE was found to be downregulated
in OA bone, which is consistent with the increased trabecular
bone volume in OA. MMP25 (upregulated in OA bone)
encodes a metalloproteinase that plays a role in MMP2
activation [59], and MMP2 is a major effector in osteocytes,
with MMP2-/- mice exhibiting disrupted osteocytic networks
and altered bone remodelling and mineralization [60]. The
MMP2-/- mice have a complex bone phenotype that includes
reduced bone volume in the long bones. Upregulation of
MMP25 in OA bone is consistent with increased activity of
MMP2 and increased bone volume.
Interestingly, and in contrast to the large number of differen-
tially expressed genes identified in OA bone with osteoblast-
related and osteocyte-related roles, a substantial group of top-
ranking differentially expressed genes identified in OP bone
(data not shown) have known or suspected roles in osteoclast-
lineage cells. The change in expression of these genes as a
group is consistent with increased osteoclast numbers, activ-
ity and bone resorption, leading to the reduction of bone vol-
ume seen in OP. There was also a group of differentially
expressed genes identified in OA bone that have known or
potential roles in osteoclast function (Tables 3 to 5). However,
the overall change in expression of these genes, as a group,
was not as consistent as for those genes identified with oste-
oblast-related functions. For instance, the change in expres-
sion of a subset of these genes (ADAMTS4, GADD45B,
IGFBP3 and CSTA) is consistent with decreased osteoclast
activity and increased bone volume in OA, whereas the
change in expression of another subset of these osteoclast-
related genes (ADAM8, STC1, CCR2, RAC2, CRYAB,
CYP1B, CD14, PTEN, ANXA2 and GSN) suggests upregu-
lated osteoclast activity (Table 6). It is now becoming clear
that, in addition to osteoblasts being intimately involved in
influencing osteoclast-lineage cell differentiation and function
[61], the converse may also be true [62,63]. As a result, per-
turbed osteoblast or osteoclast gene expression could lead to
complex changes in communication between these bone cell
types and their remodelling behaviour in OA bone. Therefore,
differential expression of a subset of the osteoclast-related
genes, suggesting upregulated osteoclast activity, is consist-
ent with the increased levels of bone remodelling seen in OA
bone and perhaps a net gain of under-mineralized bone rather
than the net loss of bone volume seen in OP.
Important inter-relationships between bone remodelling and
angiogenesis are also now emerging, and so perturbations to
angiogenic molecular pathways could contribute to the
changes seen in OA bone. Consistent with a role for increased
angiogenesis in OA bone, leading to increased bone volume
and potentially turnover, is the upregulation of a group of top-
Figure 2
PCR analysis of WNT5B, ITGB2, MMP25 and SMAD3 expression between females and males in OA boneI ,    expression bet een fe ales and males in OA bone. For each gene, a graph depicts relative 
real-time PCR product/GAPDH cycle threshold (CT) ratios generated from osteoarthritis (OA) and control (CTL) female and male intertrochanteric 
bone samples analyzed. The mean of eight samples for each sample group analyzed is represented by black diamonds (mean values given along-
side). Asterisks signify statistical significance (P < 0.01) for differential gene expression between OA and CTL bone. F, female; M, male.Page 14 of 21
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Bone related-functions of a selection of differentially expressed genes in osteoarthritis bone
Gene Description/function References
Bone remodeling, osteoblast: upregulated in osteoarthritis (OA) bone
S100A4 Negative regulator of matrix mineralization in osteoblasts [88,89]
MMP25 Metalloproteinase with role in matrix metalloproteinase (MMP)2 activation. Mice lacking MMP2 have disrupted 
osteocytes and altered bone mineralization
[59,60]
Bone remodeling, osteoblast: downregulated in OA bone
MEPE Extracellular matrix protein, highly expressed in osteocytes [58]
IBSP Major constituent of the bone matrix, thought to initiate and regulate mineralization [90]
MT2A Metallothionein proteins (also MT1L and MT1G) have roles in regulating osteoblast differentiation and 
mineralization
[91,92]
ADM Adrenomedullin stimulates osteoblast activity, but also interacts with and influences the effects of key bone 
regulators insulin-like growth factor (IGF)1 and transforming growth factor (TGF)-β [93,94]
STC1 Stanniocalcin inhibits calcium uptake and has inhibitory effect on bone growth during development [95,96]
IGFBP3 Constitutive over-expression of IGF1-binding protein (IGFBP)3 impairs osteoblast proliferation and bone 
formation
[97]
GADD45B Mice deficient in GADD45B protein have defective bone mineralization [98]
ADAMTS4 Metalloproteinase involved in remodelling extracellular matrix. Upregulated in fracture healing. Expressed in 
osteocytes and osteoblasts
[99,100]
LTF Lactotransferrin is an anabolic bone factor [101]
DF Adipsin inhibits osteoblastogenesis [102]
Bone remodeling, osteoclast: upregulated in OA bone
ADAM8 Stimulatory role in osteoclast formation and differentiation [103]
CCR2 Receptor for CC chemokine ligand (CCL)2, which promotes recruitment and fusion of monocytes/osteoclast 
precursors
[104]
RAC2 Member of the Rho-GTPase subfamily. Involved in organisation of cytoskeleton and adhesion of osteoclasts to 
bone
[105]
CD14 Monocyte/osteoclast precursor marker. CD14-deficient mice have increased bone mass [106,107]
ANXA2 Stimulates osteoclast precursor proliferation and differentiation through production of granulocyte-macrophage 
colony-stimulating factor (GMCSF) and receptor activator of nuclear factor-kB ligand (RANKL)
[108]
GSN Gelsolin deficiency in mice blocks podosome assembly in osteoclasts and produces increased bone mass [109]
ITGB2 Adhesion molecule important in cell-to-cell contacts during the early stage of osteoclast development [110,111]
Bone remodeling, osteoclast: downregulated in OA bone
IGFBP3 Over-expression of IGFBP3 in mice increases osteoclast number and bone resorption [97]
STC1 Stanniocalcin suppresses osteoclast activity [96]
PTEN Over-expression of PTEN suppresses RANKL-stimulated signal transduction during osteoclast differentiation [112]
FOXP1 Transcriptional repressor that has role in modulating monocyte differentiation [113]
PDE4A Down-regulated during monocyte to macrophage/osteoclast differentiation [114]
WNT pathway components and modulators: upregulated in OA bone
WNT5B WNT ligand with roles in osteoblastogenic and chondrogenic differentiation [68,69,70]
CTNNB1 Mice lacking b-catenin in osteoblasts develop severe osteopenia with increased osteoclastogenesis and 
impaired osteoblastogenesis
[115]
AKT3 Member of the AKT kinase family. Role in regulating osteoblast lifespan [116,117]
NHERF1 Mediates parathyroid hormone receptor signalling. Interacts with b-catenin, potentiating the effects of parathyroid 
hormone (PTH) on WNT signalling in bone.
[118,119]Page 15 of 21
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angiogenic functions (MMP25, S100A4, FOSB, TFF3, CTSG
and LTB) and downregulation of a group of genes that nega-
tively influence angiogenesis (HIG2, ADAMTS4, ANGPTL4,
STC1, KLF6, IGFBP3, TIMP4 and GDF15).
In addition, a subset of the genes with roles in osteoblasts,
particularly those that encode secreted, cell surface and extra-
cellular matrix molecules, including ADM, IBSP, MMP25,
STC1, IGFBP3, WNT5B, FST, TGFB1, BMP5 and INHBA,
also have potential chondrogenic functions. Altered expres-
sion of many of these genes is consistent with the proposal
that similar altered expression of these genes in osteoblasts in
the subchondral bone microenvironment could interfere with
chondrocyte or cartilage metabolism. For instance, ADM,
which is downregulated in OA bone has a pro-chondrogenic
role [64]. Reduced levels of ADM could negatively affect
chondrocyte/cartilage metabolism.
The second significant and connected observation from this
study was that many of the top-ranking differentially expressed
genes identified in OA bone (with osteoblast, osteocyte and
osteoclast related roles) were WNT or TGF-β/BMP signalling
pathway target genes. This observation, on closer examination
of the ranked list of differentially expressed in OA bone, led to
the identification of additional sets of differentially expressed
genes that were WNT or TGF-β/BMP signalling pathway com-
ponent or modulator genes. These data together suggest that
the WNT and TGF-β/BMP signalling pathways are altered in
OA bone and may play a role(s) in OA pathogenesis. Both the
WNT and TGF-β/BMP signalling pathways have been impli-
cated in influencing bone mass and bone remodelling [32-34]
and have been demonstrated to do this by controlling both
osteoblast and osteoclast differentiation and function [65-67].
WNT signalling, in terms of bone mass and bone remodelling,
is a very complex process that depends on the interplay of a
large number of WNT ligands, the receptors they complex
with, prevailing antagonists and particular combinations of β-
catenin/transcription factor complexes that ultimately control
the expression of the target genes. Interestingly, the only gene
encoding a WNT ligand, WNT5B, that was identified as being
differentially expressed (upregulated in OA bone) in the
present study was recently demonstrated to increase in
expression during in vitro osteoblast differentiation [68]. The
protein encoded by WNT5B is known to have both stimulatory
and inhibitory effects on bone and cartilage cells, and signals
through both the canonical and noncanonical WNT signalling
pathways, depending on the receptor it complexes with at the
cell surface [68-70]. Along with WNT5B, there were also sev-
eral other important WNT pathway related genes that were
altered in their expression in OA bone. Genes for the WNT5B
co-receptor FZD3 and extracellular WNT antagonist SFRP5
were under-expressed, relative to controls, suggesting
increased WNT signalling. Downregulation of the intracellular
signalling cascade genes PTEN, APC and AXIN2, and upreg-
ulation of CTNNB1, AKT3 and NHERF1 are also consistent
with increased WNT signalling. CTNNB1 encodes β-catenin,
which is the central downstream mediator of canonical WNT
signalling, which forms a complex with lymphoid enhancer fac-
WNT pathway components and modulators: downregulated in OA bone
FZD3 WNT5B co-receptor [120]
PTEN Modulates/antagonises WNT signalling. Roles in osteoclast and osteoblast differentiation [112,117]
APC Loss of APC in mice leads to increased bone mass [115]
AXIN2 Negatively regulates both expansion of osteoprogenitors and maturation of osteoblasts through its modulation of 
WNT signalling
[121]
TGF-β/bone morphogenic protein (BMP) pathway components and modulators: upregulated in OA bone
ACVR1 BMP and activin A receptor. Mutation in receptor causes ectopic osteogenesis [122]
SMAD3 Important mediator of TGF-β signalling and regulator of osteoblastogenesis and bone formation [80,82]
ID1 Transcription factor with roles in bone formation and osteoblast proliferation and differentiation [123]
RUNX2 Key transcription factor involved in promoting osteoblast differentiation [76]
TGF-β/BMP pathway components and modulators: downregulated in OA bone
TGFB1 Growth factor with key role in regulating bone development and metabolism [34,80]
INHBA TGF-β family member. Can act as either inhibitor or activator of bone formation and osteoblast differentiation [124,125]
BMP5 Secreted signalling molecule involved in skeletal development and genetically implicated in OA [29]
FST TGF-β/BMP antagonist that inhibits osteoblast differentiation [126]
Table 6 (Continued)
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target gene expression [71], whereas PTEN, APC, AXIN2,
AKT3 and NHERF1 gene products modulate β-catenin activ-
ity (Table 6).
Like WNT signalling, TGF-β/BMP signalling is similarly com-
plex, with a large family of ligands, cognate receptors and
intracellular signalling molecules involved in the pathway,
exerting both stimulatory and inhibitory effects on bone remod-
elling. Several TGF-β/BMP signalling pathway component and
modulator genes that influence osteoblast function, bone
remodelling and bone mineralization were identified as altered
in OA bone. These included TGFB1, INHBA, ACVR1, BMP5,
FST and SMAD3 (Table 6).
There is significant crosstalk between the WNT and TGF-β/
BMP signalling pathways. β-Catenin, SMAD3 and runt-related
transcription factor (RUNX)2 potentially play important roles in
mediating the crosstalk between the WNT and TGF-β/BMP
signalling pathways via direct interactions and in complexes
with the TCF/LEF transcription factor family members in the
nucleus [72-75]. We observed increased RUNX2 expression
in OA bone in this study, which is consistent with increased
osteoblast differentiation and activity in OA bone. RUNX2,
which is a WNT inducible gene, encodes a transcription factor
that plays roles in mediating both WNT and TGF-β/BMP sig-
nalling, and is essential for osteoblast differentiation and skel-
etal development [66,75-77]. Intriguingly, decreased
expression of RUNX2 has been shown to reduce cartilage
destruction and subchondral bone changes in a mouse joint
instability OA model [78], suggesting a role for increased
RUNX2 expression in OA pathogenesis. An important role for
RUNX2 in OA pathogenesis is supported by our microarray
data. The products of several of the top-ranking differentially
expressed genes identified, such as TWIST1 (twist homo-
logue 1) [79], FOXF1 (forkhead box F1), ID1 (inhibitor of DNA
binding 1), HDAC4 (histone deacetylase 4) and SMAD3,
modify RUNX2 expression or interact with and modify RUNX2
function. SMAD3 is an important mediator of TGF-β regulation
of bone mechanical properties and composition [80]. TGF-β
represses RUNX2, and one of the ways it does this is through
recruitment of the histone deacetylase HDAC4 by SMAD3
[81]. However, SMAD3 over-expression (SMAD3 was upreg-
ulated in OA bone in the present study) has also been
reported to induce RUNX2 expression and osteoblast differ-
entiation [82]. Significantly, several of the highest ranking dif-
ferentially expressed genes identified in this study in OA bone
are targets of RUNX2 and SMAD3, such as GADD45B [83],
ADAMTS4 [84] and MEPE [82].
Finally, the molecular mechanisms that are responsible for the
greater incidence of OA in females are not known. Genes may
operate differently in the two sexes, at different body sites and
on different disease features within body sites [27]. Interest-
ingly, of the relatively small number of differences between
females and males in OA bone identified in this study, there
were significant numbers of genes that were involved in both
osteoclast (for example, ANXA2, GSN, ITGB2, FOXP1 and
PDE4A) and osteoblast (LTF, DF and TGFB1) function and
hence bone remodelling (Tables 5 and 6). Collectively, the dif-
ferential expression of these genes is consistent with
increased bone turnover in OA females compared with males,
suggesting an OA disease mechanism and perhaps partly
accounting for a greater incidence of OA in females than in
males.
A number of the highest ranking differentially expressed genes
between OA females and males include WNT signalling path-
way components such as WNT5B and the transcription factor
genes EAF2 and CTBP2. In addition MMP25 and ITGB2 are
WNT target genes, suggesting a difference between females
and males in WNT signalling that may have an impact on the
OA bone microenvironment. There is also evidence of cross-
talk between WNT and oestrogen signalling pathways via
functional interaction between β-catenin and oestrogen recep-
tor-α [85]. A number of the genes identified in our study,
including WNT5B, ITGB2, GSN, VCAM1, LTF and DF, are
affected by oestrogen, potentially providing a mechanism by
which they are differentially expressed in females compared
with males. Examples of sexual dimorphism in mammalian
gene expression related to different responses to disease by
females and males are beginning to be identified [86]. The dif-
ferences in expression levels of WNT5B, ITGB2 and MMP25
detected between females and males in OA bone is of interest
and marks these genes as good candidates for further investi-
gation into the sex disparity in OA.
In this study we observed small gene expression ratios in both
microarray and real-time PCR analyses. These are probably
contributed by the complex mix of cells being assayed, along
with the subtle changes to bone that are observed in OA distal
to the affected joint, and the often slow, age-dependent onset
of the disease. Furthermore, OA is a multifactorial, multigene
disorder (and perhaps even a heterogenous group of disor-
ders that lead to similar bone changes, cartilage degeneration
and ultimately loss of joint function). Therefore, it is to be
expected that many genes and small changes in the expres-
sion of these genes would be involved in OA pathogenesis.
Microarray analysis is able to reliably detect small (<2-fold)
changes that prove to be biologically relevant [87], and in our
study we were able to confirm the large majority of the differ-
entially expressed genes by real-time PCR analysis.
Furthermore, the power of the microarray analysis approach
lies in its ability to detect genome-wide, coordinated, or simi-
larly regulated differential gene expression, pointing to per-
turbed signalling pathways and importantly downstream
molecular processes. Our study has identified such relation-
ships between commonly regulated target genes (via WNT
and TGF-β/BMP signalling pathways) that play roles, in partic-Page 17 of 21
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influencing bone formation, mineralization and remodelling.
Conclusion
In conclusion, we identified altered gene expression in bone
from individuals with primary hip OA at a site distal to the
diseased joint. This information is of interest because it identi-
fies genes that potentially play roles in systemic physiological
bone turnover or in skeletal disease processes, and implicate
altered WNT and TGF-β/BMP signalling in OA pathogenesis.
Further work sampling from individuals with early OA will be
required to determine whether the genes identified as differen-
tially expressed in OA bone are causal or secondary to the
altered bone seen in OA.
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